Abstract
Formestane, a new selective aromatase inhibitor devoid of severe side-effects, has been shown to be active in patients with advanced breast cancer. To investigate the clinical activity and endocrinological effects of formestane as a first-line treatment, 52 patients were administered two different doses: 24 received 250 mg formestane and 28 received 500 mg formestane i.m. fortnightly. All of the patients had a performance status of 2 or less (ECOG scale), 34 (65%) had a disease-free interval of at least 2 years and 21 (40%) were both oestrogen-receptor- and progesterone-receptor-positive; 20 patients received hormone and 13 received chemotherapeutical adjuvant treatment. Objective responses were obtained in 8 patients in the 250-mg group (33%; 95% CI: 14%-52%) and in 13 patients in the 500-mg group (46%;, 95% CI.: 28%-64%). The median response duration in the two groups was respectively 11 and 12 months. E2 serum levels of oestradiol had significantly (P
Original language | English |
---|---|
Pages (from-to) | 378-382 |
Number of pages | 5 |
Journal | Journal of Cancer Research and Clinical Oncology |
Volume | 121 |
Issue number | 6 |
DOIs | |
Publication status | Published - Jun 1995 |
Keywords
- Aromatase inhibitors
- Breast neoplasm
- Formestane
- Hormonal treatment
- Postmenopause
ASJC Scopus subject areas
- Oncology
- Cancer Research